Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-017-11321-x http://scihub22266oqcxt.onion/10.1038/s41598-017-11321-x C5589740!5589740!28883482     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Rep 2017 ; 7 (ä): ä Nephropedia Template TP {{tp|p=28883482|t=2017. Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis |pdf=|usr=}}{{28883482}} gab.com Text Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=28883482 #FOAvip After the commercialization of nintedanib in Japan, a high incidence of hepatotoxicity resulting in treatment interruption was noted in idiopathic pulmonary fibrosis (IPF) patients treated with nintedanib in our hospital. This study aimed to clarify the risk factors for hepatotoxicity of nintedanib. Sixty-eight consecutive cases of IPF newly treated with nintedanib at a dose of 150?mg twice daily from September 2015 to September 2016 were enrolled: 46 patients (67.6%) exhibited aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) elevation and 16 patients (23.5%) also had a Common Terminology Criteria for Adverse Events (CTCAE) grade ?2. Body surface area (BSA) was significantly lower in the CTCAE grade ?2 group than in another group. A multivariate logistic regression analysis showed that the association between BSA and AST/ALT elevation with CTCAE grade ?2 was statistically significant. Eight of 10 patients who resumed nintedanib at a reduced dose of 100?mg twice daily after interruption due to hepatotoxicity did not again develop AST/ALT elevation. In conclusion, a low BSA was associated with hepatotoxicity of nintedanib at a dose of 150?mg twice daily. It would be a good option for patients with a small physique to start nintedanib at a dose of 100?mg twice daily and then increase if possible after confirming its safety. Twit Text FOAVip Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=28883482 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28883482 #FOAvip English Wikipedia <ref>{{Cite pmid|28883482}}</ref> Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis #MMPMID28883482 Ikeda S; Sekine A; Baba T; Yamanaka Y; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Okudela K; Iwasawa T; Ohashi K; Takemura T; Ogura T Sci Rep 2017[]; 7 (ä): ä PMID28883482show ga After the commercialization of nintedanib in Japan, a high incidence of hepatotoxicity resulting in treatment interruption was noted in idiopathic pulmonary fibrosis (IPF) patients treated with nintedanib in our hospital. This study aimed to clarify the risk factors for hepatotoxicity of nintedanib. Sixty-eight consecutive cases of IPF newly treated with nintedanib at a dose of 150?mg twice daily from September 2015 to September 2016 were enrolled: 46 patients (67.6%) exhibited aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) elevation and 16 patients (23.5%) also had a Common Terminology Criteria for Adverse Events (CTCAE) grade ?2. Body surface area (BSA) was significantly lower in the CTCAE grade ?2 group than in another group. A multivariate logistic regression analysis showed that the association between BSA and AST/ALT elevation with CTCAE grade ?2 was statistically significant. Eight of 10 patients who resumed nintedanib at a reduced dose of 100?mg twice daily after interruption due to hepatotoxicity did not again develop AST/ALT elevation. In conclusion, a low BSA was associated with hepatotoxicity of nintedanib at a dose of 150?mg twice daily. It would be a good option for patients with a small physique to start nintedanib at a dose of 100?mg twice daily and then increase if possible after confirming its safety. äLow body surface area predicts hepatotoxicity of nintedanib in patient(epmc).pdf DeepDyve Pubget Overpricing